Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL

Clinical trial NCT07301424 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07301424
Sponsor: University of Alberta
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)BCR-ABL Positive Acute Lymphoblastic Leukemia

Start date: 2027-01-02
Primary completion: 2027-12-31
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.